Aims: To assess whether nursing home (NH) residents with type 2 diabetes mellitus (T2D) preferentially received "T2D-friendly" (vs "T2D-unfriendly") β-blockers after acute myocardial infarction (AMI), and to evaluate the comparative effects of the two groups of β-blockers.
| INTRODUCTION
Clinicians must consider comorbidities such as type 2 diabetes mellitus (T2D) when prescribing guideline-recommended medications for secondary prevention, such as β-blockers after acute myocardial infarction (AMI). 1, 2 Previous studies have shown that non-vasodilating β-blockers, such as metoprolol and atenolol, are associated with increases in glycated haemoglobin (HbA1c), mean plasma glucose, body weight and triglycerides. 3, 4 By contrast, vasodilating β-blockers such as carvedilol, nebivolol and labetalol, have been associated with reduced HbA1c levels. 3, 4 These vasodilating β-blockers, so-called "T2D-friendly" β-blockers, may be a more optimal choice for patients with T2D, although few data are available on actual clinical outcomes. 5, 6 Previous studies in younger populations have shown that utilization of T2D-friendly β-blockers among patients with T2D
is low. 7 No evidence currently exists on whether clinicians preferentially prescribe T2D-friendly β-blockers to frail, older adults with T2D
after AMI, or whether the choice of β-blocker affects clinically relevant outcomes for these individuals. The evidence gap is especially pronounced for the oldest and frailest individuals in the US population: nursing home (NH) residents. These questions are important because NH residents have a high burden of AMI and T2D, 8, 9 and are particularly sensitive to the adverse effects of medications. [8] [9] [10] Age-related changes in pharmacokinetics, such as decreased hepatic and renal drug clearance, could lead to prolonged medication halflives and increased plasma concentrations. 11, 12 The increased availability of drug in the body could potentiate both the desired and unintentional effects of β-blockers. 8 Moreover, the complex effects of β-blockers may yield different outcomes in vulnerable older adults compared with younger, healthier adults in whom these and most other drugs are typically studied. On the one hand, T2D-friendly β-blockers may reduce plasma glucose levels and could therefore reduce the risk of hyperglycaemia. On the other hand, their effects on peripheral vasodilation may increase the risk of orthostatic hypotension and subsequently increase the risk of falls and fractures. 13 Each of these consequences could be detrimental to older adults, specifically frail NH residents. Yet, clinical trials have excluded frail older adults, creating a gap in the evidence base. 14 This gap, as well as the vulnerability of older NH residents, warrants a comparison of T2D-friendly β-blockers to "T2D-unfriendly" β-blockers.
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The objectives of the present study, therefore, were (1) to determine if older NH residents with T2D preferentially receive T2D-friendly β-blockers after AMI, and (2) to evaluate the potential benefits and harms of T2D-friendly β-blockers in older NH residents after AMI. We hypothesized that NH residents with T2D would be preferentially prescribed T2D-friendly β-blockers.
We also hypothesized that, although T2D-friendly β-blockers would result in fewer hospitalizations for hyperglycaemia, they would increase the risk of fractures and declines in physical functioning.
| MATERIALS AND METHODS

| Data sources and study population
The data sources and study population for our study have been previously described. 8, 9, 15 18, 19 We employed a previously validated residential history file algorithm to track the timing and location of health service use. 20 The study cohort and measures of covariates have also been previously described. 8, 9, 15 In brief, we conducted a retrospective inception cohort study of a national cohort of long-stay NH residents without a history of AMI who were hospitalized for AMI, had not previously taken β-blockers for at least 4 months prior to AMI, and were re-admitted to US NHs directly after hospital discharge between May 1, 2007 and March 31, 2010 ( Figure S1 ). 9 Our final sample consisted of 15 720 NH residents admitted to 8349 NHs.
| Measures
For our first objective, our outcome was new use of a T2D-friendly β-blocker vs a T2D-unfriendly β-blocker in the immediate posthospital period. As in prior studies using the cohort, we identified oral β-blockers in Medicare Part D prescription drug claims, which contain a complete history of drug dispensing for this population, including date dispensed, dose, route and days' supply. 8, 9 T2D-friendly β-blockers theoretically have neutral or beneficial effects on blood glucose levels and other metabolic variables by increasing peripheral uptake of glucose through peripheral vasodilation. 4 As defined in previous work 7 , T2D-friendly β-blockers included all β-blockers with vasodilating properties from any mechanism, including α-1 blockade, calcium channel blockade, or nitric oxide pathways (carvedilol, nebivolol and labetalol). 3, 21, 22 We defined β-blockers without vasodilating properties as T2D-unfriendly (atenolol, bisoprolol and metoprolol).
These T2D-unfriendly β-blockers may cause more compensatory peripheral vasoconstriction by reducing cardiac output. 7 Many of them have been associated with increased insulin resistance and more atherogenic lipid profiles. 3, 7, 22, 23 The primary predictor for our first objective was the presence of a diagnosis of T2D prior to or on the day of the AMI, which we ascertained from Part A hospital claims.
For our second objective, we examined the use of T2D-friendly vs T2D-unfriendly β-blockers in the immediate post-hospital period as the exposure, and we examined outcomes within 90 days of the index hospital discharge. Primary outcomes were hypoglycaemia and hyper- [26] [27] [28] [29] [30] We measured all outcomes within 90 days of the NH readmission after the index AMI hospital discharge. 8 
| Analytical approach
We used the χ 2 test to initially test whether overall and T2D-friendly β-blocker use differed for individuals with T2D vs without T2D.
Among NH residents who received a β-blocker, we then evaluated univariable associations between potential predictors and T2D-friendly vs unfriendly β-blocker initiation, using logistic regression models to estimate odds ratios (ORs) with 95% confidence intervals (CIs). To test our hypothesis that certain individual and facility factors were independently associated with T2D-friendly vs T2D-unfriendly β-blocker prescribing for residents after AMI, we used a multivariable logistic regression model. 31 Because residents are clustered within NH facilities, we used multilevel modelling and included random intercepts for facilities in the models to ensure more accurate standard errors. 32 We modelled patient and facility characteristics as fixed effects.
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Among patients with T2D who were treated with a β-blocker on returning to the NH after AMI, we used propensity score-based methods to evaluate the relationship between type of β-blocker exposure and outcomes. Following the observational study analogue of an intention-to-treat exposure definition, we defined patients as T2D-friendly β-blocker users or T2D-unfriendly β-blocker users throughout the follow-up period based on their exposure in the immediate post-AMI period. We estimated the propensity score (here, the probability of receiving a T2D-friendly vs T2D-unfriendly β-blocker) via a flexible logistic regression model with 103 covariates. Covariates included sociodemographic characteristics, chronic medical conditions, baseline medication use, hospitalization history, baseline functional and cognitive status, geriatric syndromes, symptoms, characteristics of the AMI hospitalization, and NH characteristics. We then trimmed the areas of non-overlap in the propensity score distribution between the treatment groups and applied a 1:1 greedy 5-to-1 digit matching algorithm without replacement, such that each user of a T2D-friendly β-blocker was matched with a user of a T2D-unfriendly β-blocker, and the distribution of characteristics in the T2D-unfriendly group mimicked that of the T2D-friendly group. 33 We evaluated the quality of resulting matches by comparing standardized differences between groups for each covariate in our model, and by using t tests to assess differences in the distribution of propensity scores. [33] [34] [35] Within the propensity score-matched cohort, the association between T2D-friendly vs T2D-unfriendly β-blockers and all-cause mortality was estimated using a binomial logistic regression model. To estimate the association between T2D-friendly vs T2D-unfriendly β-blockers and all-cause re-hospitalization while accounting for the competing risk of death, we used multinomial logistic regression. We also used multinomial logistic regression that accounted for the competing risk of death to examine significant declines in physical functioning, as well as hospitalizations for hypoglycaemia, hyperglycaemia and fractures. At the end of the 90-day follow-up, patients were classified as being alive without an outcome event, having had an outcome event, or having died without evidence of an outcome event.
Finally, to better convey the effect of T2D-friendly vs T2D-unfriendly β-blockers on the absolute measurement scale, we calculated the absolute risk difference and numbers needed to treat or harm. The CIs for the numbers needed to treat or harm are presented in the format recommended by Altman. 3 | RESULTS (vs without T2D) were younger, more likely to be men, and more likely to have heart failure (HF), asthma and unstable angina (Table 1) . Those with T2D were taking more medications overall, and were more likely to receive antiplatelet agents, warfarin and statin medications.
| Study population
| β-blocker use
Overall, 56.9% of residents (n = 8953/15 720) initiated a β-blocker after AMI on NH readmission, including 59.5% of those with T2D and 55.8% of those without T2D (χ 2 P < 0.001). Among residents with T2D, the most commonly used β-blockers were metoprolol (66%), carvedilol (27%) and atenolol (5%). Similarly, among residents without T2D, the most commonly used β-blockers were also metoprolol (71%), carvedilol (23%) and atenolol (4%). Carvedilol accounted for 97.1% of T2D-friendly β-blocker use, labetalol for 1.7% and nebivolol for 1.1%.
Metoprolol accounted for 92% of T2D-unfriendly β-blocker use, atenolol for 7%, and bisoprolol for 1%.
Among residents who initiated a β-blocker (n = 8953), 29%
(n = 815/2855) of residents with T2D initiated a T2D-friendly β-blocker vs 24% (n = 1460/6098) of those without T2D (χ 2 P < 0.001; Tables S1 and S2) . After covariate adjustment, use of T2D-friendly β-blockers was greater in residents with T2D
(adjusted OR 1.14, 95% CI 1.00-1.29). By far the strongest predictor of T2D-friendly β-blocker use was a diagnosis of HF at baseline (Table S1 ).
| Outcomes
Propensity score matching yielded a cohort of 1530 patients with T2D, with 765 new T2D-friendly β-blocker users and 765 new T2D-unfriendly β-blocker users ( Table 2 ). The mean age was 80 years. The distribution of propensity scores was nearly identical between the matched groups (mean [SD] 0.34 [0.13] in both T2D-friendly β-blocker users and T2D-unfriendly users, P = 0.97; Figure S2 ). All 103 covariates, including NH characteristics, were well balanced between treatment groups and had standardized mean differences of ≤0.09 (Tables S3 and S4 Statin medications, n (%) 1794 (37) 2734 (25) Antiplatelet medications, n (%) 947 (20) 1671 (15) Warfarin, n (%) 643 (13) 1287 (12) Mean (SD) number of medications (last MDS assessment)
13 (5) 12 (5) AMI index hospitalization characteristics Median (IQR) length of stay, days 6 (4-9) 6 (4-9)
One or more days in CCU or ICU, n (%) The CHESS scale was designed to identify individuals at risk of serious decline. It creates a 6-point scale from 0 = not at all unstable to 5 = highly unstable, with higher levels predictive of adverse outcomes such as mortality, hospitalization, pain, caregiver stress, and poor self-rated health. 
| DISCUSSION
In our large national cohort of older NH residents who recently had an AMI, we found that having T2D was associated with a modest increase in the use of T2D-friendly β-blockers, even after adjustment for HF and other potential determinants of prescribing. Use of T2D-friendly vs T2D-unfriendly β-blockers (effectively carvedilol vs metoprolol because of the overwhelming use of these two medications)
was associated with a decrease in hospitalized hyperglycaemia and an increase in all-cause re-hospitalization, but no marked differences in death, functional decline, hypoglycaemia, or fracture. The observed association with all-cause re-hospitalization may be attributable to residual confounding by missing information on ejection fraction, but this suspicion is not empirically testable in the data; therefore, the potential trade-off between a reduction in hospitalized hyperglycaemia (number needed to treat 64, 95% CI 34-715) and a larger magnitude increase in all-cause re-hospitalization (number needed to harm 21, 95% CI 11-5000) suggests that, while T2D-friendly β-blockers might optimize glycaemic outcomes, this benefit may come at the cost of more all-cause hospitalizations. Given the remaining uncertainty about confounding of the re-hospitalization effect, and because few NH residents or caregivers would accept a higher risk of worse overall outcomes to reduce the risk of a single cause of hospitalization, T2D-friendly β-blockers should not yet be widely recommended over T2D-unfriendly β-blockers after AMI until additional corroborative evidence is available for vulnerable older adults.
Basic science studies have examined the glycometabolic effects of individual β-blockers. Those studies suggest that vasodilating β-blockers may be "T2D-friendly" by increasing peripheral glucose uptake via peripheral vasodilation. 37 A more limited number of studies have examined the glycometabolic effects of individual β-blockers in clinical practice. Most notably, Arnold et al. 7 used data from the TRI-UMPH study to examine the use of T2D-friendly β-blockers in a general adult population after AMI. While the use of T2D-friendly β-blockers was low overall, their study found that T2D-friendly β-blockers were more likely to be prescribed to patients with T2D.
The primary outcome in that study was worsening glycaemic control, defined as an increase in HbA1c, among those with T2D at 6 months after AMI. They observed that T2D-friendly β-blockers were associated with a lower risk of worsened glycaemic control, although this association was not statistically significant. 7 Although our study did not use HbA1c as a measure, the reduction in hospitalizations for hyperglycaemia suggests that those taking T2D-friendly β-blockers had better glycaemic control than those taking T2D-unfriendly Abbreviations: ADL, activities of daily living; AI/AN/API, American Indian/Alaskan Native/Asian Pacific Islander; AMI, acute myocardial infarction; CCU, cardiac care unit; CHESS, Changes in Health, End-Stage Disease, Signs, and Symptoms; COPD, chronic obstructive pulmonary disease; HF, heart failure; ICU, intensive care unit; IQR, interquartile range; NH, nursing home; T2D, type 2 diabetes. a Percentages have been rounded and may not total 100. b Measured using the Morris 28-point scale of Independence in ADLs and categorized as 0 to 14 (independent to limited assistance required), 15 to 19 (extensive assistance required), and 20 or higher (extensive dependency). c Measured by the Cognitive Performance Scale and trichotomized as 0 to 1 (Intact to borderline intact), 2 to 3 (mild to moderate dementia), and 4 to 6 (moderately severe to very severe dementia). d Scores range from 0 to 5, with higher scores indicating greater health instability. e Cells containing a value of less than 11 and any risk (percentage) that could be used in combination with other reported information to obtain a cell of less than 11 have been suppressed to comply with the Centers for Medicare and Medicaid Services Cell Size Suppression Policy. a Positive values of the absolute risk difference indicate that individuals who received T2D-friendly β-blockers had higher risks of the outcome than taking T2D-unfriendly β-blockers; negative numbers indicate T2D-friendly β-blocker users had a lower risk than T2D-unfriendly β-blocker users. b Calculated as 1/(risk among β-blockers non-users -risk among β-blocker users). c Cells containing a value of less than 11 and any risk (percentage) that could be used in combination with other reported information to obtain a cell of less than 11 have been suppressed to comply with the Centers for Medicare and Medicaid Services Cell Size Suppression Policy.
β-blockers. This should be weighed against the potential harms of T2D-friendly β-blockers (ie, carvedilol), such as orthostatic hypotension and subsequent falls among older adults, which have been demonstrated in small prior studies. 38, 39 We cannot be certain why there was differential prescribing of T2D-friendly vs T2D-unfriendly β-blockers for certain patient groups.
One factor that could account for differences in prescribing is more involvement of cardiologists in the care of certain patient subgroups (eg, younger patients and those with more intensive care unit use)
because cardiologists are more likely to be aware of the differences between T2D-friendly and T2D-unfriendly β-blockers than non-cardiologists, and thus, may be more likely to prescribe T2D-friendly β-blockers. Another important factor could be that certain patient Pharmacotherapy for older adults in the NH setting requires special consideration, as this population is typically excluded from clinical trials and can be especially sensitive to medications and their adverse effects. 2 Our study adds to the existing literature by demonstrating that, although T2D-friendly β-blockers may help optimize glycaemic outcomes after AMI among older NH residents with T2D, who represent nearly a third of the NH population with AMI, this benefit may come at the cost of a higher risk of all-cause re-hospitalization. On the relative effect scale, the estimate for all-cause re-hospitalization appears modest (OR 1.26) while the estimate for hyperglycaemia appears to be relatively large (OR 0.45). On the absolute effect scale, the estimate for re-hospitalization (risk difference 4.84%; number needed to harm 21) is actually three times larger in magnitude than the estimate for hyperglycaemia (risk difference −1.57%; number needed to treat 64). In other words, on average, for every one hyperglycaemia hospitalization prevented, there will be three additional all-cause re-hospitalizations incurred. It is therefore important to note that, at the population level, the data suggest that systematically recommending T2D-friendly β-blockers would lead to a net increase in harm among frail, older adults, even before accounting for other potential detrimental effects that were unmeasured in the present study.
The present study has several limitations. As with any observational study, we cannot exclude the possibility of confounding. 40, 41 In particular, carvedilol-the most common T2D-friendly β-blocker-is prescribed more often for individuals with HFrEF. Although we adjusted for measures of HF, residual confounding may still remain; however, the measured baseline covariates, including HF, were well balanced between T2D-friendly and T2D-unfriendly β-blocker users after matching. The balance achieved for HF may be attributable to the fact that metoprolol, a T2D-unfriendly β-blocker, and carvedilol, a T2D-friendly β-blocker, are both effective options for AMI and HF treatment. 42 Nonetheless, we do not have information on ejection fraction or HF severity, which affect the choice of β-blocker and the risk of adverse health outcomes. If such confounding exists, one might expect an elevated risk of adverse health outcomes (eg, re-hospitalizations) among T2D-friendly β-blocker users because those drugs (eg, carvedilol) are more likely to be used in individuals with HF; however, while ejection and HF severity might confound the relationship between T2D-friendly vs T2D-unfriendly β-blocker use and all-cause hospitalization, these covariates are unlikely to significantly confound the relationship with hyperglycaemia and hypoglycaemia hospitalizations.
Another limitation is that we were unable to differentiate STelevation myocardial infarction (STEMI) from non-STI-elevation myocardial infarction (NSTEMI) during the index AMI hospitalization, which may have influenced prescribing and induced residual confounding. Although current AMI guidelines for STEMI 1 and NSTEMI 43 are quite similar regarding β-blocker therapy recommendations, this
was not the case with earlier guidelines in place during the study period. 44, 45 The 2007 STEMI guidelines provide detailed guidance for the use of metoprolol, without specific recommendations for other β-blockers. 45 The 2007 guidelines for NSTEMI emphasize the use of metoprolol, atenolol and carvedilol. 44 Another notable limitation of our study cohort was the lack of information on HbA1c to help diagnose T2D or adjust for confounding by glycaemic control, which future studies using Veterans Affairs or other data should aim to address. However, we did adjust for proxies for glycaemic control, including pre-AMI history of hypoglycaemia hospitalization, hyperglycaemia hospitalization, and diabetes medication use. Information about T2D was obtained from Part A hospital claims, which may be a less sensitive measure than HbA1c. Our study had limited statistical power to detect small differences for rare outcomes, although larger studies are unlikely to be conducted. Because of the nature of our data, we were unable to conduct as-treated analyses to account for β-blocker discontinuation, to conduct analyses of β-blocker dose to assess dose-response relationships with outcomes, or to examine whether T2D-friendly and T2D-unfriendly β-blockers were prescribed at equipotent doses. Previous work in this study population, however, suggests that NH residents who started β-blockers after AMI typically continued them until 90 days of follow-up and, as long as discontinuations were non-differential by treatment group, estimates are likely to be attenuated toward the null. Finally, the present study focused on the immediate post-AMI period, which may affect the generalizability of our results to other periods in residents' stay in the NH if unique characteristics of the post-AMI period modify the relationship between β-blocker use and outcomes. Other limitations of the study cohort have been previously described. 8, 9, 15 In conclusion, in a large national cohort of older NH residents with recent hospitalization for AMI, initiation of T2D-friendly β-blockers was unassociated with death, functional decline, hypoglycaemic events or fracture events compared with initiation of T2D-unfriendly β-blockers. Although residual confounding remains a plausible explanation and more corroborative data would be helpful, especially on other outcomes such as orthostatic hypotension and falls, T2D-friendly β-blockers were associated with a reduction in hospitalization for hyperglycaemia and an increase in all-cause re-hospitalization. Given that, in addition to all-cause re-hospitalization, T2D-friendly β-blockers may also be associated with other detrimental effects that were unmeasured in the present study, they should not be preferentially prescribed despite their potential advantage for glycaemic control. was also provided by the National Heart, Lung, and Blood Institute (5R01HL111032) and National Institute on Aging (K24AG049057).
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